Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
Emerging biotechnologies: full report - Nuffield Council on Bioethics
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
E m e r g i n g b i o t e c h n o l o g i e s<br />
commercialisati<strong>on</strong> problems 9.36, 9.38–<br />
9.39, 9.41<br />
incentivising 9.60–9.69<br />
type 2 emerging <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g> 9.34, 9.37<br />
commercialisati<strong>on</strong> problems 9.40<br />
incentivising 9.70<br />
type 3 emerging <str<strong>on</strong>g>biotechnologies</str<strong>on</strong>g> 9.34, 9.37<br />
Type I and Type II errors 5.31<br />
UK Genetic Testing Network 8.25<br />
uncertainty 3.1, 3.3–3.12, 3.37–3.38, 10.4<br />
commercialisati<strong>on</strong> problems 9.48–9.51<br />
effects of framing 3.32–3.34<br />
managing 3.26–3.36<br />
public discourse ethics 4.44<br />
public perspectives 5.3<br />
regulatory aspects 8.12–8.14, 8.35<br />
risk and 3.10–3.12<br />
varieties of 3.5–3.9<br />
unc<strong>on</strong>trolled uses 3.9, Box 3.1<br />
Understanding risk (1996, US Nati<strong>on</strong>al<br />
Research <str<strong>on</strong>g>Council</str<strong>on</strong>g>) 5.24<br />
unintended c<strong>on</strong>sequences 1.1, 3.8<br />
United Kingdom (UK)<br />
GM food crops 2.8, 5.22, 8.13, 8.18, 8.29<br />
'good at research, bad at commercialisati<strong>on</strong>'<br />
7.21, 7.23–7.32<br />
health impact fund 9.62–9.63<br />
importance of research impact 6.38–6.42<br />
regulatory systems 8.21–8.25<br />
research and innovati<strong>on</strong> policy 7<br />
research funding 6.7–6.10<br />
research settings 6.5<br />
see also Government, UK<br />
United States (US)<br />
GM crops 2.8, 8.18<br />
importance of research impact 6.38<br />
influences over the media 5.15–5.16<br />
orphan drugs 9.20<br />
patent protecti<strong>on</strong> 9.23–9.24<br />
research funding 6.10<br />
universities 6.5<br />
impact agenda 6.38–6.46<br />
research and profit-seeking 9.10–9.12<br />
unknown unknowns 3.11<br />
upstream public engagement 5.40–5.42<br />
utilitarian ethics 4.24–4.25<br />
utility, research 6.42–6.43<br />
industry 6.27–6.35<br />
procedural narratives 2.36–2.38<br />
see also expectati<strong>on</strong>s<br />
water power Box 3.3<br />
Wellcome Trust 6.14, 7.18, 7.46, 7.58<br />
Wellcome Trust Sanger Institute 6.5<br />
winners, technological 1.26<br />
wisdom of repugnance 4.12<br />
World Health Organizati<strong>on</strong> (WHO) 8.25, 9.61<br />
World Wide Web 3.8, 5.11<br />
xenobiology 2.22<br />
xeno-nucleic acid 2.22<br />
xenotransplantati<strong>on</strong> 2.11, 2.42<br />
yuck factor 4.12<br />
vaccinati<strong>on</strong> 4.35, Box 1.1<br />
vaccines, producti<strong>on</strong> of 8.23<br />
'valley of death' 7.24, 9.42–9.43<br />
J. Craig Venter Institute 3.18, Box 3.2<br />
venture capitalism 6.13, 6.22, 7.40, 9.7, 9.43<br />
viral genomes, synthetic 2.20<br />
virtual patients 1.14, 6.12<br />
virtues, procedural 4.43–4.55, 4.57<br />
visi<strong>on</strong>s, biotechnology 1.4, 2.29–2.38, 2.45<br />
ambiguous 3.14–3.16<br />
future 2.34–2.35<br />
208